Pretreatment weight trajectory and early dosing were associated with response.
The research question
What distinguishes early oral Wegovy super-responders?
Overview
Retrospective EHR analysis examined 9,287 GLP-1-naive patients prescribed oral Wegovy.
Study design & methods
Among 8,381 patients with baseline weight, 3,011 had follow-up weights at 30–180 days. Groups reflected best weight change; super-response meant >10% loss.
Principal findings
Super-responders lost 11.4% by day 90. Systolic pressure fell 10.2 mmHg versus 3.3 mmHg in non-responders. They had greater prior five-year weight gain and faster early dose escalation.
Limitations & interpretation
Preprint; not peer reviewed. Outcome-defined groups, selective follow-up, and short observation limit inference. Associations do not establish causality or justify faster titration; prospective validation is needed.
Publication type and venue follow the original nference listing. Read the original paper for full methods, analyses, and interpretation. View source listing.